New epilepsy drug candidate iQ-007 enters first human safety trial

NCT ID NCT06899230

Ongoing Knowledge-focused Sponsor: iQure Australia Pty Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests the safety of an experimental oral drug called iQ-007 in 72 healthy volunteers. The drug is designed to help control seizures by boosting the brain's ability to clear excess glutamate, a chemical linked to epilepsy. The study does not yet test if it works for seizures, only whether it is safe and how the body processes it.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: iQ-007 (an experimental oral drug that may help control seizures by boosting glutamate transport in the brain)
What this could lead to: If safe and effective in later trials, iQ-007 could become a new treatment option for people with drug-resistant epilepsy and focal seizures.
What could go wrong: This is an early Phase 1 safety study in only 72 healthy people, not patients. It does not test if the drug actually works for epilepsy, and many drugs fail in later stages.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRUG-RESISTANT EPILEPSY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Drug Resistant Epilepsy focal epilepsy visual epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DRUG-RESISTANT EPILEPSY FOCAL SEIZURE

Contacts and locations

Locations

CMAX Clinical Research Pty Ltd

Adelaide, South Australia, 5000, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.